Investing.com - Exagen (NASDAQ:XGN) reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Exagen announced earnings per share of $-0.47 on revenue of $14.7M. Analysts polled by Investing.com anticipated EPS of $-0.76 on revenue of $9.13M.
Exagen shares are down 63% from the beginning of the year, still down 85.01% from its 52 week high of $14.01 set on November 15, 2021.
Exagen follows other major Healthcare sector earnings this month
Exagen's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar